GlassScriptPhysician profile
Yamini P Chennu
NPI 1548210263
$17,787.88
in general payments reported to CMS, 2019-2025
74 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,980 · 2020: $2,180 · 2021: $2,774 · 2022: $2,454 · 2023: $2,231 · 2024: $2,698 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,315 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,315.42 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,039.82 | 2019-2025 | Botox, Ubrelvy, Duopa |
| Ucb, INC. | $1,654.59 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Biogen, INC. | $1,221.50 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Novartis Pharmaceuticals Corporation | $1,032.20 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $987.25 | 2019-2025 | Nuplazid, Daybue |
| Neurocrine Biosciences, INC. | $544.26 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $516.13 | 2019-2022 | |
| Eisai INC. | $478.96 | 2019-2025 | |
| Amgen INC. | $472.03 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $430.05 | 2019-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $421.11 | 2019-2025 | Amyvid, Kisunla, Reyvow |
| Allergan, INC. | $420.79 | 2019-2022 | |
| Celgene Corporation | $404.82 | 2021-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $338.15 | 2019-2023 | |
| Genentech USA, INC. | $325.13 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamini Chennu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.